 NEW HAVEN, Conn., Jan. 19, 2023 GLOBE NEWSWIRE BIOASIS TECHNOLOGIES INC. OTCQB:BIOAF; TSX.V:BTI the Company or Bioasis, a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 TM platform for delivering therapeutics across the blood-brain barrier BBB and the treatment of central ... The post Bioasis Announces Filing of Its Quarterly Financial Statements and MDA for th... 